Cancer diagnoses are projected to hit 2.1 million in 2026, even as decades of progress have driven a 35% decline in the ...

Genomic testing in high-risk prostate cancer remains underutilized nationally, driven by fragmented ordering and interpretive ...

For robotic radical prostatectomy, the Retzius-sparing approach permits early urinary continence recovery but prostate cancer outcomes might be compromised.

The New Era of Tumor-Agnostic Cancer Therapy / ALK, Allen Chen, BCR ABL, Bence Jones proteins, biomarkers, BRAF, CA 19-9, ...

A single patient with one of the rarest and most aggressive salivary gland malignancies has provided oncologists with an ...

IMFINZI with IMJUDO and Platinum-Based Chemotherapy Immune-mediated pneumonitis occurred in 3.5% (21/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy, ...

Men with high-risk prostate cancer have a higher likelihood of having residual disease following prostatectomy and may require radiation ...

The core significance extends far beyond the pharmaceutical product itself, encompassing broader medical implications, public health value, and long-term impacts on patient care that redefine the true ...

Must-Read Posts In GU Oncology This Week / cancer, cancer care, Cancer research, cancer treatment, clinical trials, GU ...

A recent analysis of the NRG-RTOG 0534 "SPPORT" clinical trial evaluated the Luminal B (LumB) molecular subtype using the PAM50 genomic ...

Meibomian gland carcinoma is one of the rarest and most treacherous malignancies in ocular oncology, and for decades it has ...